134 related articles for article (PubMed ID: 10586395)
1. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin.
Karol MD; Locke CS; Cavanaugh JH
J Clin Pharmacol; 1999 Dec; 39(12):1283-9. PubMed ID: 10586395
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
3. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment.
Karol MD; Locke CS; Cavanaugh JH
J Clin Pharmacol; 2000 Mar; 40(3):301-8. PubMed ID: 10709160
[TBL] [Abstract][Full Text] [Related]
4. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone.
Cavanaugh JH; Karol MD
J Clin Pharmacol; 1996 Nov; 36(11):1064-71. PubMed ID: 8973995
[TBL] [Abstract][Full Text] [Related]
5. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
[TBL] [Abstract][Full Text] [Related]
6. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
Tolman KG; Sanders SW; Buchi KN; Karol MD; Jennings DE; Ringham GL
J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
[TBL] [Abstract][Full Text] [Related]
7. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Dilger K; Zheng Z; Klotz U
Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
9. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
10. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Gunasekaran T; Gupta S; Gremse D; Karol M; Pan WJ; Chiu YL; Keith R; Fitzgerald J
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S327-35. PubMed ID: 12607793
[TBL] [Abstract][Full Text] [Related]
12. Influence of lansoprazole treatment on diazepam plasma concentrations.
Lefebvre RA; Flouvat B; Karolac-Tamisier S; Moerman E; Van Ganse E
Clin Pharmacol Ther; 1992 Nov; 52(5):458-63. PubMed ID: 1424419
[TBL] [Abstract][Full Text] [Related]
13. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
14. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
17. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
Hussein Z; Granneman GR; Mukherjee D; Samara E; Hogan DL; Koss MA; Isenberg JI
Br J Clin Pharmacol; 1993 Nov; 36(5):391-8. PubMed ID: 12959285
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
19. No influence of pantoprazole on the pharmacokinetics of phenytoin.
Middle MV; Müller FO; Schall R; Groenewoud G; Hundt HK; Huber R; Bliesath H; Steinijans VW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S72-5. PubMed ID: 8793606
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Freston JW; Chiu YL; Mulford DJ; Ballard ED
Aliment Pharmacol Ther; 2003 Feb; 17(3):361-7. PubMed ID: 12562448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
